Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects

被引：0
作者：
Shamizadeh S. [1 ]
Brockow K. [1 ]
Ring J. [1 ,2 ]
机构：
[1] Department of Dermatology and Allergy Biederstein, Technische Universität, Munich
[2] Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, Biedersteiner Straße 29, München
来源：
Allergo Journal International | 2014年 / 23卷 / 3期
关键词：
allergic rhinitis; Antihistamines; chronic urticaria; platelet-activating factor; Rupatadine;
D O I：
10.1007/s40629-014-0011-7
中图分类号：
学科分类号：
摘要：
Rupatadine is a modern non-sedating H1-antihistamine that also haswith additional antagonist effects on platelet-activating factor (PAF). Under the tradenames Rupafin® and Urtimed®, Rrupatadine is approvedregistered in Germany for the treatment of allergic rhinitis and urticaria infor adults and children aged over 12 years. In this review, the available literature available to date onregarding the pharmacological profile and clinical application of Rrupatadine is reviewed and compared to other conventional histamines. In conclusionFinally, the side effects, safety and interaction profileincompatibility of Rrupatadine are discussed. Due to CYP p450 metabolism, Rrupatadine should not be given together with Eerythromycin, Kketoconazole or grapefruit juice. Rupatadine has been found to be effective and safe Iin a variety of randomized clinical trials both in both seasonal and perennial allergic rhinitis, as well as inbut also chronic urticaria Rupatadine has been found as effective and safe. © 2014, Urban & Vogel.
引用
收藏
页码：87 / 95
页数：8
相关论文
共 58 条
  • [1] Simons F.E., Simons K.J., Histamine and H1-antihistamines: celebrating a century of progress, J Allergy Clin Immunol, 128, pp. 1139-1150, (2011)
  • [2] Merlos M., Giral M., Balsa D., Ferrando R., Queralt M., Puigdemont A., Et al., Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF), J Pharmacol Exp Ther, 280, pp. 114-121, (1997)
  • [3] Vuurman E., Theunissen E., van Oers A., van Leeuwen C., Jolles J., Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers, Hum Psychopharmacol, 22, pp. 289-297, (2007)
  • [4] Izquierdo I., Merlos M., Garcia-Rafanell J., Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis, Drugs Today (Barc), 39, pp. 451-468, (2003)
  • [5] Rupafin® Fachinformation, (2009)
  • [6] del Cuvillo A., Mullol J., Bartra J., Davila I., Jauregui I., Montoro J., Et al., Comparative pharmacology of the H1 antihistamines, J Investig Allergol Clin Immunol, 16, pp. 3-12, (2006)
  • [7] Katiyar S., Prakash S., Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis, Prim Care Respir J, 18, pp. 57-68, (2009)
  • [8] Mullol J., Bousquet J., Bachert C., Canonica W.G., Gimenez-Arnau A., Kowalski M.L., Et al., Rupatadine in allergic rhinitis and chronic urticaria, Allergy, 63, 87, pp. 5-28, (2008)
  • [9] Izquierdo I., Nieto C., Ramis J., Cooper M., Dewland P., Forn J., Pharmacokinetics and dose linearity of rupatadine fumarate in healthy volunteers, Methods Find Exp Clin Pharmacol, 19, pp. 189-203, (1997)
  • [10] Ring J., Angewandte Allergologie, (2004)
123456